# Point-of-care Measurement of the Antifibrinolytic Activity of Tranexamic Acid in Cardiac Surgery

> **NCT06128330** · PHASE4 · RECRUITING · sponsor: **Insel Gruppe AG, University Hospital Bern** · enrollment: 322 (estimated)

## Conditions studied

- Antifibrinolytic Agents

## Interventions

- **DRUG:** Tranexamic acid bolus 20 mg/kg
- **DRUG:** Tranexamic acid bolus 10 mg/kg
- **DRUG:** Tranexamic acid bolus 1 mg/kg
- **DRUG:** Tranexamic acid continuous infusion of 1 mg/kg/h in the low dose group

## Key facts

- **NCT ID:** NCT06128330
- **Lead sponsor:** Insel Gruppe AG, University Hospital Bern
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-12-15
- **Primary completion:** 2025-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 322 (ESTIMATED)
- **Last updated:** 2025-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06128330

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06128330, "Point-of-care Measurement of the Antifibrinolytic Activity of Tranexamic Acid in Cardiac Surgery". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06128330. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*